Pfizer in talks to merge off-patent drugs business with Mylan

(Reuters) - Pfizer Inc <PFE.N> is in talks to merge its off-patent drugs business with Mylan NV <MYL.O> in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Mylan shareholders would receive a little more than 40% of the newly formed entity, with Pfizer shareholders receiving the remainder, the Journal said, adding Pfizer would also get about $12 billion in proceeds from a new sale of debt.

Pfizer and Mylan did not immediately respond to requests for comment.

(Reporting by Maria Ponnezhath in Bengaluru; Editing by Mark Potter)